binimetinib

Term ID

CHEBI:145371

Synonyms

5-(4-bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide
5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
ARRY 162
ARRY 438162
ARRY-162
ARRY-438162
binimetinib
binimetinibum
MEK-162
MEK162
Mektovi
N-(2-hydroxyethoxy)-4-fluoro-5-(2-fluoro-4-bromophenylamino)-1-methyl-1H-benzoimidazole-6-carboxamide
NVP-MEK162

(all 14)

Definition

A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib.

References

(all 27)

Ontology

ChEBI ( EBI )

Relationships

is a type of: benzimidazoles bromobenzenes hydroxamic acid ester monofluorobenzenes secondary amino compound

benzimidazoles bromobenzenes hydroxamic acid ester monofluorobenzenes secondary amino compound Show first 5 Terms
has_role: antineoplastic agent apoptosis inducer EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor

antineoplastic agent apoptosis inducer EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor Show first 5 Terms

Phenotype

Phenotype resulting from binimetinib

Phenotype where environments contain binimetinib

Phenotype modified by environments containing binimetinib

Phenotype affecting binimetinib

Human Disease Model